Search

Your search keyword '"Kizmazoglu, D."' showing total 47 results
Start Over Author "Kizmazoglu, D."
47 results on '"Kizmazoglu, D."'

5. Turkish Pediatric Oncology Group Neuroblastoma 2009 Protocol Intermediate Risk Group Treatment Results

Author

Tokuc, G., Oguz, A., Beker, B., Yildirim, Z., Unal, E., Kantar, M., Yesil, S., Emir, S., Corapcioglu, F., Oniz, H., Dagdemir, A., Erbay, A., Koksal, Y., Aksoylar, S., Guler, E., Tugcu, D., Kebudi, R., Sevinir, B., Demirag, B., Akici, F., Varan, A., Kurucu, N., Sari, N., Kupeli, S., Apak, H., Bozkurt, C., Hazar, V., Kose, D., Ozguven, A., Ozyoruk, D., Kizmazoglu, D., Olgun, N., Cecen, E., Ince, Dilek, Cakir, F., Citak, C., and Yoruk, A.

Published
2020

44. Infantile Hemangiomas of the Head and Neck: A Single-Center Experience.

Author

Kizmazoglu D, Ince D, Olgun Y, Cecen E, Guleryuz H, Erdag T, and Olgun N

Abstract

Background: Infantile hemangiomas (IHs) are the most common benign vascular tumors of infancy. Methods: We report our experiences with 248 patients with head and neck IHs. Results: The median admission age was 4 months, and the female/male ratio was 2.18. Among the cases, 45% were followed by no treatment. No local complications were observed in any of these patients. Propranolol was provided to all patients who received medical treatment. The median duration of treatment was 12 months (1-30 months), and the median follow-up period of all patients was 14 months (0-118 months). The treatment response was 98%. The complication rate was 17%, and children aged between 3 and 9 months accounted for 60% of the patients who developed complications. Most of the complications were local complications, such as ulceration and bleeding. Conclusions: Although most IHs regress spontaneously, complications may occur. Propranolol alone is an effective treatment option, and early treatment initiation increases the success rate.

Published
2024
Full Text
View/download PDF

45. Pediatric paravertebral tumors: analysis of 96 patients.

Author

Kizmazoglu D, Ince D, Cecen E, Kizmazoglu C, Guleryuz H, Ozer E, Demiral A, and Olgun N

Subjects
Child, Humans, Male, Female, Child, Preschool, Retrospective Studies, Pain, Sarcoma, Histiocytosis, Langerhans-Cell complications, Spinal Cord Compression etiology
Abstract

Purpose: The most important complication of paravertebral tumors is cord compression (CC), which is an oncologic emergency. Early and appropriate intervention is important in terms of reducing morbidity and mortality. Here, we report our clinical experience with paravertebral tumors., Methods: The files of patients who were followed up for benign/malignant paravertebral tumors between 1988 and 2022 were evaluated retrospectively., Results: There were 96 patients with paravertebral tumors. The median age at diagnosis was 5 years (1 month-17 years). The male/female ratio was 1.13. The median time to diagnosis was 4 weeks (0-28 weeks). The most common presenting complaint was pain (62.5%). The diagnosis distribution was as follows: sympathetic nervous system (SNS) tumors (n: 38), soft tissue sarcomas (STS) (n: 23), Langerhans cell histiocytosis (LCH) (n: 12), central nervous system (CNS) tumors (n: 9), germ cell tumor (n: 6), lymphomas (n: 4), and benign tumors (n: 4). Sixty-five patients (67.7%) had CC, 40% of whom received chemotherapy as first-line treatment. Decompression surgery was performed in 58.5% of the patients. For patients with CC, 26 patients had advanced disease at admission. Serious neurologic sequelae were observed in seventeen (17.7%) patients., Conclusion: Pain and neurological findings in childhood are warning signs for paravertebral tumors and CC. A detailed neurologic examination and radiodiagnostic imaging should be performed, and a definitive diagnosis should be made quickly. Anticancer treatment should be planned multidisciplinary. Decompression surgery should be discussed for patients with severe neurological deficits. Childhood cancers are chemosensitive; if possible, treatment should be initiated with chemotherapy to avoid neurological sequelae., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

46. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.

Author

Olgun N, Cecen E, Ince D, Kizmazoglu D, Baysal B, Onal A, Ozdogan O, Guleryuz H, Cetingoz R, Demiral A, Olguner M, Celik A, Kamer S, Ozer E, Altun Z, and Aktas S

Abstract

Background: Relapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of immunotherapy with dinutuximab beta (DB) and chemotherapy in patients with relapsed/refractory high-risk neuroblastoma., Methods: All patients received the Turkish Pediatric Oncology Group NB 2009 national protocol for HR-NB treatment at the time of diagnosis. Salvage treatments were administered after progression or relapse. The patients who could not achieve remission in primary or metastatic sites were included in the study. The most common chemotherapy scheme was irinotecan and temozolomide. DB was administered intravenously for 10 days through continuous infusion with 10 mg/m 2 per day. The patients received 2 to 14 successive cycles with duration of 28 days each. Disease assessment was performed after cycles 2, 4, and 6 and every 2 to 3 cycles thereafter., Results: Between January 2020 and March 2022, nineteen patients received a total of 125 cycles of DB and chemotherapy. Objective responses were achieved in 12/19 (63%) patients, including complete remission in 6/19 and partial response in 6/19. Stable disease was observed in two patients. The remaining five patients developed bone/bone marrow and soft tissue progression after 2-4 cycles of treatment. The most common Grade ≥3 toxicities were leukopenia, thrombocytopenia, hypertransaminasemia, fever, rash/itching and capillary leak syndrome, respectively., Conclusion: Our study results suggest that DB-based chemo-immunotherapy seems to be suitable with encouraging response rates in patients with relapsed/refractory high-risk neuroblastoma., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Olgun, Cecen, Ince, Kizmazoglu, Baysal, Onal, Ozdogan, Guleryuz, Cetingoz, Demiral, Olguner, Celik, Kamer, Ozer, Altun and Aktas.)

Published
2022
Full Text
View/download PDF

47. Successful treatment of congenital systemic juvenile xanthogranulomatosis with pulmonary involvement.

Author

Ataseven E, Kizmazoglu D, and Oniz H

Subjects
Female, Humans, Histiocytosis, Langerhans-Cell diagnosis, Histiocytosis, Langerhans-Cell drug therapy, Histiocytosis, Non-Langerhans-Cell, Skin Neoplasms, Xanthogranuloma, Juvenile diagnosis, Xanthogranuloma, Juvenile drug therapy
Abstract

Juvenile xanthogranuloma (JXG) is a common form of non-Langerhans cell histiocytosis, which usually presents with spontaneously regressing skin lesions. Systemic involvement is rare and mostly seen in patients with multiple skin nodules. It can spontaneously regress, but sometimes systemic involvement can cause life-threatening symptoms and can be fatal. Herein, we report a case of congenital systemic JXG with multiple skin nodules, soft tissue and pulmonary involvement. She was successfully treated with chemotherapy according to Langerhans cell histiocytosis treatment protocol IV of the Histiocyte Society (LCH-IV)., (© 2021 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results